NeurotoxicityPhase 3NCT00489411
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
A Phase 3 study testing duloxetine hydrochloride in people with Neurotoxicity and Pain, run by Alliance for Clinical Trials in Oncology at 475 sites in United States.
Trial summary
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. Read more about this study
- Who is it for?
- Ages 25 years and older
- Conditions the study is for
- Neurotoxicity, Pain, Peripheral Neuropathy
- What is being tested?
- duloxetine hydrochloride
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 231 participants
- Where
- 475 sitesUnited States
- Study dates
- Apr 2008to Mar 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Diagnosis of cancer
- CNS malignancy allowed with the exception of leptomeningeal carcinomatosis
- Must have painful sensory chemotherapy-induced peripheral neuropathy (CIPN) resulting from prior treatment with single-agent taxane or platinum agents (paclitaxel, docetaxel, nab-paclitaxel, oxaliplatin, cisplatin) (may not have received drugs from both classes)
- CIPN > grade 1 as measured by NCI-CTCAE v 4.0
- Average neuropathic pain score ≥ 4
- Patients with the following illnesses known to cause peripheral neuropathy are eligible, provided they have no evidence of neuropathy from these illnesses:
- Diabetes mellitus
- Peripheral vascular disease
- HIV infection
- Significant degenerative or familial neurologic disorder known to cause peripheral neuropathy
- No clinical or subclinical neuropathy from nerve compression injuries (i.e., carpal tunnel syndrome, brachial plexopathy, spinal stenosis, or spinal nerve root compression)
PATIENT CHARACTERISTICS:
- AST ≤ 3 times upper limit of normal
- Total bilirubin ≤ normal
- Creatinine clearance > 30 mL/min
- Not pregnant or nursing
- Able to take oral or enteral medication
- No history of seizure disorder
- No diagnosis of ethanol addiction or dependence within the past 10 years
- No history of narrow-angle glaucoma
- None of the following:
- History of suicidal thoughts
- Symptoms of or history of schizophrenia, bipolar disease, or a major depression
- Serious eating disorder such as bulimia or anorexia where electrolyte imbalance is likely
PRIOR CONCURRENT THERAPY:
- At least 3 months since prior and no concurrent taxane or platinum agent
- At least 14 days since prior and no concurrent monoamine oxidase inhibitors or other antidepressants
- No other prior or concurrent neurotoxic drugs (e.g., vincristine, vinblastine, cytarabine, thalidomide, bortezomib, carboplatin, or procarbazine)
- No concurrent anticonvulsants
- No concurrent B or E vitamin supplementation in doses greater than the recommended daily allowance (RDA)
- Centrum (standard formula) and One-A-Day "essential" formula which contain 100% RDA for vitamins B6, E, and B12 allowed
- Other multivitamins allowed provided they contain no more than 100% RDA of B vitamins and vitamin E
- No concurrent treatment (pharmacologic) for depression
Trial locations and contacts
475 sites in 1 country.
300 sites in 1 country
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
New York Oncology Hematology, PC at Albany Regional Cancer Care
Albany, New York, 12206
New York Oncology Hematology, PC at Albany Medical Center
Albany, New York, 12208
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic, PC
Ames, Iowa, 50010
Amsterdam Community Cancer Program
Amsterdam, New York, 12010
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Cancer Resource Center at King's Daughters Medical Center
Ashland, Kentucky, 41101-0151
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Sturdy Memorial Hospital
Attleboro, Massachusetts, 02703
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
Barberton Citizens Hospital
Barberton, Ohio, 44203
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
MeritCare Bemidji
Bemidji, Minnesota, 56601
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Study site
Bettendorf, Iowa, 52722
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
St. Joseph Medical Center
Bloomington, Illinois, 61701
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Peninsula Medical Center
Burlingame, California, 94010
Aurora Memorial Hospital of Burlington
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Illinois CancerCare - Canton
Canton, Illinois, 61520
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Waverly Hematology Oncology
Cary, North Carolina, 27511
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, 94546
Iowa Blood and Cancer Care
Cedar Rapids, Iowa, 52402
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599-7295
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Martha Jefferson Hospital Cancer Care Center
Charlottesville, Virginia, 22901
Saint Luke's Hospital
Chesterfield, Missouri, 63017
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, 60612-3785
Resurrection Medical Center
Chicago, Illinois, 60631
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic - Chippewa Center
Chippewa Falls, Wisconsin, 54729
MetroHealth Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
John B. Amos Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Cancer Care Center at John Muir Health - Concord Campus
Concord, California, 94524-4110
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Danville Regional Medical Center
Danville, Virginia, 24541
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Kaiser Permanente - Denver
Denver, Colorado, 80205
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80224-2522
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Doylestown Hospital Cancer Center
Doylestown, Pennsylvania, 18901
Delaware County Regional Cancer Center at Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Shore Regional Cancer Center at Memorial Hospital - Easton
Easton, Maryland, 21601
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
Elkhorn, Wisconsin, 53121
Union Hospital Cancer Program at Union Hospital
Elkton MD, Maryland, 21921
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Community Cancer Center
Elyria, Ohio, 44035
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Center for Cancer Care at Exeter Hospital
Exeter, New Hampshire, 03833
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
Fergus Falls Medical Group, PA
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Great Lakes Cancer Institute at McLaren Regional Medical Center
Flint, Michigan, 48532
McLeod Regional Medical Center
Florence, South Carolina, 29501
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Oncology Alliance - Franklin
Franklin, Wisconsin, 53132
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Kaiser Permanente - Fremont
Fremont, California, 94538
Valley Medical Oncology
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Oncology Alliance, SC - Milwaukee - East
Glendale, Wisconsin, 53212-1038
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
Bendheim Cancer Center at Greenwich Hospital
Greenwich, Connecticut, 06830
Self Regional Cancer Center at Self Regional Medical Center
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Illinois CancerCare - Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Northern Montana Hospital
Havre, Montana, 59501
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
High Point Regional Hospital
High Point, North Carolina, 27261
Emerywood Hematology/Oncology
High Point, North Carolina, 27262
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
New York Oncology Hematology, PC - Hudson
Hudson, New York, 12534
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
Queens Cancer Center of Queens Hospital
Jamaica, New York, 11432
Mercy Regional Cancer Center
Janesville, Wisconsin, 53547
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Oncology Alliance - Kenosha South
Kenosha, Wisconsin, 53143
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists
Kinston, North Carolina, 28501
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Kaiser Permanente - Lafayette
Lafayette, Colorado, 80026
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
Lakeland, Florida, 33805
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
New York Oncology Hematology, PC - Latham
Latham, New York, 12110
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756-0002
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67905
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80501
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
McDonough District Hospital
Macomb, Illinois, 61455
Dean Medical Center - Madison
Madison, Wisconsin, 53717
Norris Cotton Cancer Center at Catholic Medical Center
Manchester, New Hampshire, 03102
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Vince Lombardi Cancer Clinic - Marinette
Marinette, Wisconsin, 54143
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County
Martinsville, Virginia, 24115
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
St. Luke's Hospital
Maumee, Ohio, 43537
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Aurora Advanced Healthcare East Mequon Clinic
Mequon, Wisconsin, 53092
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53201-0342
Medical Consultants, Limited
Milwaukee, Wisconsin, 53215
Oncology Alliance, SC - Milwaukee - South
Milwaukee, Wisconsin, 53215
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Trinity CancerCare Center
Minot, North Dakota, 58701
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Illinois CancerCare - Monmouth
Monmouth, Illinois, 61462
OSF Holy Family Medical Center
Monmouth, Illinois, 61462
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Camino Medical Group - Treatment Center
Mountain View, California, 94040
El Camino Hospital Cancer Center
Mountain View, California, 94040
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
New York Weill Cornell Cancer Center at Cornell University
New York, New York, 10021
Mount Sinai Medical Center
New York, New York, 10029
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Michiana Hematology Oncology PC - Niles
Niles, Michigan, 49120
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Illinois CancerCare - Community Cancer Center
Normal, Illinois, 61761
Fisher-Titus Medical Center
Norwalk, Ohio, 44857
About this study
Official title: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Read the detailed description
OBJECTIVES:
Primary
- Determine the efficacy of duloxetine hydrochloride in cancer patients with painful chemotherapy-induced (taxane or platinum agent) peripheral neuropathy.
Secondary
- Determine the influence of this drug on peripheral neuropathy-related functional status and quality of life of these patients.
- Describe the differences in duloxetine hydrochloride efficacy when used to treat pain caused by chemotherapy-induced peripheral neuropathy based on the neurotoxic drug and class.
OUTLINE: This is a randomized, double-blind, placebo-controlled, crossover study. Patients are stratified according to prior neurotoxic agent (paclitaxel vs oxaliplatin vs other taxane agents without paclitaxel vs platinum agents [cisplatin] without oxaliplatin) and high risk for developing painful chemotherapy-induced peripheral neuropathy (no vs yes). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
- Arm II: Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
Patients complete pain and quality of life questionnaires, including the BPI-SF once weekly and FACT/GOG-NTX and EORTC QLQ-C30 questionnaires, in weeks 1, 6, 8, and 13.
After completion of study treatment, patients are followed for 2 weeks.
- Conditions
- Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- Being tested
- duloxetine hydrochloride, placebo
- Keywords
- unspecified adult solid tumor, protocol specific, neurotoxicity, pain, peripheral neuropathy
- Medical subject headings
- Neurotoxicity Syndromes, Pain, Peripheral Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
duloxetine hydrochlorideDrug
Given orally
placeboOther
Given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I/Group A (Duloxetine then Placebo) | Experimental | Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13. Receives: Drug: duloxetine hydrochloride; Other: placebo |
| Arm II/Group B (Placebo then Duloxetine) | Experimental | Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13. Receives: Drug: duloxetine hydrochloride; Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item
Change in average pain from Week 1 to Week 5, measured on day 1 of Weeks 1 and 6 by the Brief Pain Inventory Short Form (BPI-SF) was calculated as value at Day 1 of Week 1 minus value at Day 1 of Week 6 to yield positive improvement values. The BPI-SF contains 4 items assessing average, worst, least, and intermediate pain severity in the last 24 hours. Pain severity items are scored using an 11-point numeric rating scale (0, no pain; 10, pain as bad as you can imagine). Average pain severity was chosen as the primary outcome based on recommendations from the Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT). Patients completed the BPI-SF when thinking only about pain from peripheral neuropathy. The Cronbach's alpha reliability for the BPI ranges between 0.77 and 0.91. The comparison of interest was the difference between the 2 treatment groups in pain change during the initial treatment period.
Measured: Day 1 of Week 1 to Day 1 of Week 6
Secondary outcomes (3)
Change in Pain-related Functional Interference Score From Week 1 to Week 5, as Measured by the BPI-SF Interference Score
Change in pain-related functional interference score during the initial treatment period (Week 1 to Week 5), as measured by the BPI-SF interference score: Using an accepted method for accessing the influence of pain on function, 7 BPI-SF items were used to quantify the degree to which pain interfered with daily activities or function (0, does not interfere; 10 completely interferes). The 7 items were summed to obtain a total interference score, which ranged from 0 to 70, with lower scores meaning less interference. The mean change in pain-related functional interference score during the initial treatment period are reported below for each treatment arm and was calculated as value at Day 1 of Week 1 minus value at Day 1 of Week 6 to yield positive improvement values.
Measured: Day 1 of Week 1 to Day 1 to Week 6
Change in the Total Score of the FACT/COG-NTX From Week 1 to Week 5
Patient-reported QOL was assessed using the Functional Assessment of Cancer Treatment, Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale on day 1 of weeks 1, 6, 8, and 13. The instrument contains 11 questions, assessing numbness, tingling, and discomfort in the hands or feet; difficulty hearing; tinnitus; joint pain or muscle cramps; weakness; or trouble walking, buttoning buttons, or feeling small shapes when placed in the hand. Items are scored from 0 to 4 (o, not at all; 4, very much) and summed (total score range, 0-44, with higher scores indicating a worse outcome). A 2- to 3-point change is defined as a clinically meaningful improvement in QOL per published recommendations specific to similar measures. The Mean Change During Initial Treatment Period in the FACT/GOG-Ntx total score are reported for each treatment arm and was calculated as value at Day 1 of Week 1 minus value at Day 1 of Week 6 to yield positive improvement values.
Measured: Day 1 of Week 1 to Day 1 of Week 6
Change in Average Pain From Week 8 to Week 12, as Measured by the BPI-SF Average Pain Severity Item
Change in average pain from Week 8 to Week 12, measured on day 1 of Weeks 8 and 13 by the Brief Pain Inventory Short Form (BPI-SF) was calculated as value at Day 1 of Week 8 minus value at Day 1 of Week 13 to yield positive improvement values. The BPI-SF contains 4 items assessing average, worst, least, and intermediate pain severity in the last 24 hours. Pain severity items are scored using an 11-point numeric rating scale (0, no pain; 10, pain as bad as you can imagine). Average pain severity was chosen as the primary outcome based on recommendations from the Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT). Patients completed the BPI-SF when thinking only about pain from peripheral neuropathy. The Cronbach's alpha reliability for the BPI ranges between 0.77 and 0.91. The comparison of interest was the difference between the 2 treatment groups in pain change during the crossover treatment period.
Measured: Day 1 of Week 8 to Day 1 of Week 13
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jun 2007 (estimated)
- Study startApr 2008
- Primary completionJan 2012
- Study completionMar 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for NeurotoxicityStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 231 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Ellen L. Smith, PhD, ARNP, AOCN, Study chair, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00489411
- Sponsor's protocol ID
- CALGB-170601
- Other IDs
- CALGB-170601, CDR0000553389
- Status last verified
- Mar 2017
- First submitted
- 20 Jun 2007
- Last updated
- 26 Apr 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Lavoie Smith EM, Pang H, Cirrincione C, et al.: CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). [Abstract] J Clin Oncol 30 (Suppl 15): A-CRA9013, 2012.
Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Le-Lindqwister N, Fadul CE, Loprinzi C, Shapiro CL; Alliance for Clinical Trials in Oncology. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017 Mar;26(2):10.1111/ecc.12421. doi: 10.1111/ecc.12421. Epub 2015 Nov 25.
PubMed 26603828Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813.
PubMed 23549581
Study at a glance
From the registry record, last updated by the sponsor on 26 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
- ClinicalTrials.gov ID
- NCT00489411
- Acronym / sponsor ID
- CALGB-170601
- Conditions
- Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- Keywords
- unspecified adult solid tumor, protocol specific, neurotoxicity, pain, peripheral neuropathy
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 231 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Apr 2008
- Primary completion
- Jan 2012 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 21 Jun 2007 (estimated)
- Results
- Posted 26 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Detailed description
OBJECTIVES:
Primary
- Determine the efficacy of duloxetine hydrochloride in cancer patients with painful chemotherapy-induced (taxane or platinum agent) peripheral neuropathy.
Secondary
- Determine the influence of this drug on peripheral neuropathy-related functional status and quality of life of these patients.
- Describe the differences in duloxetine hydrochloride efficacy when used to treat pain caused by chemotherapy-induced peripheral neuropathy based on the neurotoxic drug and class.
OUTLINE: This is a randomized, double-blind, placebo-controlled, crossover study. Patients are stratified according to prior neurotoxic agent (paclitaxel vs oxaliplatin vs other taxane agents without paclitaxel vs platinum agents [cisplatin] without oxaliplatin) and high risk for developing painful chemotherapy-induced peripheral neuropathy (no vs yes). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
- Arm II: Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
Patients complete pain and quality of life questionnaires, including the BPI-SF once weekly and FACT/GOG-NTX and EORTC QLQ-C30 questionnaires, in weeks 1, 6, 8, and 13.
After completion of study treatment, patients are followed for 2 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I/Group A (Duloxetine then Placebo) | Experimental | Drug: duloxetine hydrochloride, Other: placeboPatients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13. |
| Arm II/Group B (Placebo then Duloxetine) | Experimental | Drug: duloxetine hydrochloride, Other: placeboPatients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13. |
Who may qualify
- Ages
- 25 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| duloxetine hydrochlorideGiven orally | Drug | Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) |
| placeboGiven orally | Other | Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) |
Primary outcome
Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item
Time frame: Day 1 of Week 1 to Day 1 of Week 6
Change in average pain from Week 1 to Week 5, measured on day 1 of Weeks 1 and 6 by the Brief Pain Inventory Short Form (BPI-SF) was calculated as value at Day 1 of Week 1 minus value at Day 1 of Week 6 to yield positive improvement values. The BPI-SF contains 4 items assessing average, worst, least, and intermediate pain severity in the last 24 hours. Pain severity items are scored using an 11-point numeric rating scale (0, no pain; 10, pain as bad as you can imagine). Average pain severity was chosen as the primary outcome based on recommendations from the Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT). Patients completed the BPI-SF when thinking only about pain from peripheral neuropathy. The Cronbach's alpha reliability for the BPI ranges between 0.77 and 0.91. The comparison of interest was the difference between the 2 treatment groups in pain change during the initial treatment period.
3 secondary outcomes
Change in Pain-related Functional Interference Score From Week 1 to Week 5, as Measured by the BPI-SF Interference Score
Time frame: Day 1 of Week 1 to Day 1 to Week 6
Change in the Total Score of the FACT/COG-NTX From Week 1 to Week 5
Time frame: Day 1 of Week 1 to Day 1 of Week 6
Change in Average Pain From Week 8 to Week 12, as Measured by the BPI-SF Average Pain Severity Item
Time frame: Day 1 of Week 8 to Day 1 of Week 13
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Apr 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publicationLavoie Smith EM, Pang H, Cirrincione C, et al.: CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). [Abstract] J Clin Oncol 30 (Suppl 15): A-CRA9013, 2012.
- Derived from this study: PubMed 26603828Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Le-Lindqwister N, Fadul CE, Loprinzi C, Shapiro CL; Alliance for Clinical Trials in Oncology. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017 Mar;26(2):10.1111/ecc.12421. doi: 10.1111/ecc.12421. Epub 2015 Nov 25.
- Derived from this study: PubMed 23549581Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813.
Related trials for Neurotoxicity
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
RecruitingObservational study
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Lymphoma, Leukemia
Not yet recruitingPhase 1
Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
Not yet recruitingObservational study
RPM Signals in Outpatient CAR T Therapy
Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome
RecruitingPhase 2
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ellen L. Smith, PhD, ARNP, AOCN study chair
University of Michigan
475 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing duloxetine hydrochloride in people with Neurotoxicity and Pain, run by Alliance for Clinical Trials in Oncology at 475 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 475 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item (time frame: Day 1 of Week 1 to Day 1 of Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00489411, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2017.